Long noncoding RNA BHLHE40‐AS1 promotes early breast cancer progression through modulating IL‐6/STAT3 signaling
Autor: | Cristian Coarfa, Ali S. Ropri, Emilio O. Herrera, William P. Smith, Rebecca Sinnott DeVaux, Jason I. Herschkowitz, Peter A. Hall, Fariba Behbod, Sandra L. Grimm, Sridar V. Chittur |
---|---|
Rok vydání: | 2020 |
Předmět: |
STAT3 Transcription Factor
0301 basic medicine Breast Neoplasms Biochemistry Article 03 medical and health sciences 0302 clinical medicine Breast cancer Cell Movement Cell Line Tumor Ductal carcinoma in situ (DCIS) Basic Helix-Loop-Helix Transcription Factors Tumor Microenvironment medicine Humans Neoplasm Invasiveness RNA Antisense Overdiagnosis skin and connective tissue diseases Interleukin 6 STAT3 neoplasms Molecular Biology Cell Proliferation Homeodomain Proteins biology Interleukin-6 business.industry Gene Expression Profiling Cell Cycle Interleukin Cell Biology Ductal carcinoma medicine.disease Long non-coding RNA Gene Expression Regulation Neoplastic body regions Carcinoma Intraductal Noninfiltrating 030104 developmental biology 030220 oncology & carcinogenesis Disease Progression Cancer research biology.protein Female RNA Long Noncoding business Signal Transduction |
Zdroj: | J Cell Biochem |
ISSN: | 1097-4644 0730-2312 |
Popis: | Ductal carcinoma in situ (DCIS) is a nonobligate precursor to invasive breast cancer. Only a small percentage of DCIS cases are predicted to progress; however, there is no method to determine which DCIS lesions will remain innocuous from those that will become invasive disease. Therefore, DCIS is treated aggressively creating a current state of overdiagnosis and overtreatment. There is a critical need to identify functional determinants of progression of DCIS to invasive ductal carcinoma (IDC). Interrogating biopsies from five patients with contiguous DCIS and IDC lesions, we have shown that expression of the long noncoding RNA BHLHE40-AS1 increases with disease progression. BHLHE40-AS1 expression supports DCIS cell proliferation, motility, and invasive potential. Mechanistically, BHLHE40-AS1 modulates interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3) activity and a proinflammatory cytokine signature, in part through interaction with interleukin enhancer-binding factor 3. These data suggest that BHLHE40-AS1 supports early breast cancer progression by engaging STAT3 signaling, creating an immune-permissive microenvironment. |
Databáze: | OpenAIRE |
Externí odkaz: |